Table 2.
List of circulating circRNAs reported as potential biomarkers in breast cancer.
| circRNA | Biological Source | Comparison | Expression in Tumor Specimens |
Clinical Interest | Diagnostic Value (ROC) | Experimental Approach |
|---|---|---|---|---|---|---|
| hsa_circ_0009634 | exosomes (serum) | metastatic T vs. localized T vs. N |
up | diagnosis | - | ex vivo, in vitro, in silico [95] |
| hsa_circ_0020707 | diagnosis | - | ex vivo, in vitro, in silico [95] | |||
| hsa_circ_0064923 | diagnosis | - | ex vivo, in vitro, in silico [95] | |||
| hsa_circ_0087064 | diagnosis | - | ex vivo, in vitro, in silico [95] | |||
| hsa_circ_0104852 | diagnosis | - | ex vivo, in vitro, in silico [95] | |||
| circRNA_0005795 | T vs. N | down | diagnosis | - | ex vivo, in vitro, in silico [96] | |
| circRNA_0088088 | diagnosis | - | ex vivo, in vitro, in silico [96] | |||
| BCexoc (hsa_circ_0002190, hsa_circ_0007177, hsa_circ_0000642, hsa_circ_0001439, hsa_circ_0001417, hsa_circ_0005552, hsa_circ_0001073, hsa_circ_0000267, hsa_circ_0006404) | exosomes (plasma) | early diagnosis | AUC = 0.83 | ex vivo, in silico [97] | ||
| circCNOT2 | plasma | T vs. N | up | prognosis, prediction of therapy response | - | ex vivo, in vitro, in silico [98] |
| hsa_circ_0001785 | early diagnosis, prediction of therapy response | AUC = 0.784, Sensitivity = 0.764, Specificity = 0.699 |
ex vivo, in silico [99] | |||
| hsa_circ_0008673 | diagnosis, prognosis | AUC = 0.833, Specificity = 97.10%, Sensitivity = 55%, HR = 1.742, p = 0.047 |
ex vivo, in vitro, in silico [100,101] | |||
| hsa_circ_0017536 | diagnosis | AUC = 615, p < 0.05 | ex vivo, in vitro, in silico [102] | |||
| hsa_circ_0017650 | diagnosis | AUC = 0.758, p < 0.05 | ex vivo, in vitro, in silico [102] | |||
| hsa_circ_0069094 | diagnosis | AUC = 0.681, p < 0.05 | ex vivo, in vitro, in silico [102] | |||
| hsa_circ_0079876 | diagnosis | AUC = 0.623, p < 0.05 | ex vivo, in vitro, in silico [102] | |||
| hsa_circ_0104824 | diagnosis | AUC = 0.849, p = 0.0001, Sensitivity = 71.1%, Specificity = 75.5% |
ex vivo, in silico [103] | |||
| circCDYL (hsa_circ_0008285) | serum | diagnosis, prognosis, prediction of therapy response |
HR = 3.748, p = 0.002 | ex vivo, in vitro, in vivo, in silico [104] | ||
| circKIF4A (circ_0007255) | diagnosis, prognosis | AUC = 0.77 | ex vivo, in vitro, in vivo, in silico [105] |
Abbreviations: AUC, area under the curve; circRNAs, circular RNAs; HR, hazard ratio; N, normal samples; T, tumor samples; ROC, receiver operating characteristic.